---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004698"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:51:34.064821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee

## Summary
- Consulting term extended from March 3, 2023 through June 30, 2023.
- Monthly consulting fee set at $12,500 for services rendered during the term.
- No outstanding equity awards will vest after March 2, 2023; vesting ceased on that date.

## SEC filing metadata
- accession: 0001558370-23-004698
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/0001558370-23-004698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/acrs-20230323x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004698
- JSON: https://secwatch.observer/filing/0001558370-23-004698.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.